Pictor Holdings Inc. secures $7.5 million bridge round to accelerate commercialization of targeted proteomic platform

Pictor Holdings Inc. has closed a $7.5 million bridge round of growth capital. The funding, backed by existing investors, will be used to expand commercial partnerships, scale platform development and manufacturing capabilities, and support translational studies across key human and animal health markets in the United States and internationally.

Funding strengthens Pictor’s commercial growth and investor support

The $7.5 million bridge round brings Pictor’s total capital raised to approximately $30 million. This investment builds on the company’s commercial momentum following a strong first year at its U.S. headquarters in Carlsbad, California.

Over the past year, Pictor has launched seven commercial products, secured four strategic partnerships, and expanded its leadership team with the appointments of Dr. Terry Kelly, as Chief Operating Officer and Tim Shannon, CPA, as Chief Financial Officer. These milestones support Pictor’s strategy to advance targeted proteomics across pharma, reference laboratory, and animal health markets.

Targeted proteomic platform designed for multi-analyte, high-throughput testing

Pictor’s targeted proteomic platform, comprising PictArray^® multiplex assays, PictImager^® instrumentation, and Pictorial^© software, enables laboratories to analyze up to 20 protein targets from a single sample in under two hours. The system is designed to reduce cost and workflow complexity while delivering lower per-sample economics.

By enabling multi-analyte protein analysis from a single sample, Pictor’s platform supports a broad range of applications across pharmaceutical research, clinical reference laboratories, and animal health testing. The platform is intended to make advanced proteomic assays more accessible beyond the largest, most specialized laboratory settings.

Advancing accessibility, One Health, and sustainability goals

Pictor’s leadership emphasizes the role of its targeted proteomic platform in expanding access to protein insights and supporting One Health and sustainability objectives.

“Proteomic assays should not be limited to the largest, most specialized settings. Pictor’s platform is designed to make protein insights more accessible, practical, and economical, so more partners can use them to improve health and wellness across people and animals. By helping labs generate more information from a single sample with fewer consumables, we also see an opportunity to support One Health and sustainability goals as adoption scales,” said Dr. Platt, CEO and Co-founder, Pictor Holdings Inc.

Use of proceeds and commercialization roadmap

Proceeds from the bridge round will support the scaling of platform development and manufacturing capabilities, continued expansion of Pictor’s partner network, and advancement of large-scale translational studies across priority human and animal health markets.

Pictor expects to enter licensing stages with multiple partners within the next 12 to 18 months as it advances commercialization of its targeted proteomic platform and associated products.

Positioning for U.S.-based Series A financing

Pictor is evaluating a U.S.-based Series A financing to support the next phase of growth. Planned initiatives include further expansion of commercial operations, continued platform development, and additional strategic partnerships.

The bridge round strengthens Pictor’s commercial position and provides capital to accelerate partnerships and scale operations in advance of the anticipated Series A.

“The continued support of our existing investors reflects confidence in both the platform and the commercial model we’ve built around it. This capital positions Pictor to accelerate partnerships and scale operations as we advance toward our Series A,” said Tim Shannon, CPA, Chief Financial Officer, Pictor Holdings Inc.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>